IRC
BEAM icon

Investors Research Corp’s Beam Therapeutics BEAM Stock Holding History

Investors Research Corp’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-21
Closed -$1K – 1075
2020
Q3 		$1K Buy
+21
New +$521 ﹤0.01% 1026

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Investors Research Corp's BEAM Position: Q4 2020 in Review

Investors Research Corp sold out of Beam Therapeutics (BEAM) in Q4 2020, closing a stake of 21 shares — an estimated $1K sold.

Investors Research Corp first reported a position in BEAM in Q3 2020 and held it in 1 quarter. The position peaked at $1K in Q3 2020. 158 funds tracked by Wall St. Rank hold BEAM as of Q4 2020.

  • Investors Research Corp reported no remaining Beam Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Investors Research Corp sold 21 Beam Therapeutics shares in Q4 2020, an estimated $1K.
  • Investors Research Corp first reported a position in Beam Therapeutics in Q3 2020 and held it in 1 quarter.
  • Investors Research Corp's Beam Therapeutics position peaked at $1K in Q3 2020.
  • 158 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2020.

Based on Investors Research Corp's 13F filing for Q4 2020, filed 21 Jan 2021.